arrow
Return

Ref-1 redox activity regulates retinal neovascularization by modulating transcriptional activation of HIF-1α

delete2025-02-04
delete0
delete
OA
AI
G
Gabriella D. Hartman
A
Anbukkarasi Muniyandi
K
Kamakshi Sishtla
E
Eyram Kpenu
W
William P. Miller
B
B. Kaplan
L
Leo A. Kim
S
Sheng Liu
J
Jun Wan
X
Xiaoping Qi
M
Michael E. Boulton
M
Mark R. Kelley
T
Timothy W. Corson *
DOI:10.1096/fj.202401989RRdelete
deleteOriginal
deleteOriginal request for help
deleteShare
deleteSave
Abstract

Abstract

En 中文
Retinal neovascularization impairs visual function and is a hallmark of several neovascular eye diseases, including retinopathy of prematurity (ROP) and proliferative diabetic retinopathy (PDR). Current treatments include intravitreal injections of anti-vascular endothelial growth factor (VEGF) biologics, but these therapeutics are often accompanied by high treatment burden and resistance to therapy. Prior studies indicate that APE1/Ref-1, a multifunctional protein with both endonuclease (APE1) and redox-mediated transcriptional regulatory activity (Ref-1), activates multiple pro-angiogenic and pro-inflammatory signaling pathways by chemically reducing key cysteine residues in transcription factors, thereby activating them. Here, we investigated the previously unexplored role of Ref-1 in retinal neovascularization. We demonstrate that Ref-1 is highly expressed in endothelial cells in human PDR and in the oxygen-induced retinopathy (OIR) mouse model of retinal neovascularization. Ref-1 is also highly expressed in microglia and astrocytes in OIR. A small molecule Ref-1 redox inhibitor, APX2009, decreased retinal neovascularization in OIR after systemic delivery. In vitro, hypoxic endothelial cells did not exhibit upregulation of Ref-1 but rather increased Ref-1 nuclear localization. APX2009 decreased hypoxic endothelial cell proliferation and HIF-1 alpha transcriptional activation. Thus, Ref-1 redox activity may be a novel therapeutic target for the treatment of retinal neovascularization, making APX2009 a promising systemic therapeutic approach for the treatment of vascular retinopathies such as ROP and PDR.
Keywords:
APE1/Ref-1
hypoxia-inducible factor
oxygen-induced retinopathy
redox regulation
retinal neovascularization

Journal

FASEB Journal cover
FASEB Journal
IF:
4.2
Papers:
3.1W
Citations:
4.9W

Organization

I
indiana university system
Scholars:
3.9W
Papers: 3.5W
Citations: 38
I
Indiana University Bloomington
Scholars:
1.9W
Papers: 1.5W
Citations: 2.8W
U
university of toronto
Scholars:
14.5W
Papers: 11.9W
Citations: 165
researcher View more organizations